23 May 2013
Keywords: evotec, initiates, ph, study, p2x7, blocker, german
Article | 20 October 2008
German drug developer Evotec AG has initiated Phase I clinical studies of its proprietary, small-molecule P2X7 receptor antagonist.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 October 2008
© 2013 thepharmaletter.com